News
CEO of Novo Nordisk, maker of Wegovy, is stepping down
Danish pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, said Friday its CEO was stepping down by “mutual agreement” with the company’s board of directors, citing “recent market challenges” and a steep decline in the company’s share price.
Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...
The obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk’s Wegovy in ...
Eli Lilly & Co.’s obesity drug Zepbound helped people trim about two inches more off their waists than Novo Nordisk A/S’s ...
The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...
In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...
Eli Lilly's tirzepatide leads to 50% more weight loss compared to Novo Nordisk's semaglutide in 72-week study.
CEO resigns as Eli Lilly (LLY) dominates the weight loss drug market and compounders threaten the company's financial outlook ...
Eli Lilly and Company's Zepbound demonstrated superior weight reduction compared to Novo Nordisk's Wegovy in a 72-week ...
We recently published a list of 12 Best Major Stocks to Buy According to Billionaires. In this article, we are going to take ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback